ABEO

Business Context and Reporting Period

Company: Access Pharmaceuticals, Inc. (Note: Metadata listed "Abeona Therapeutics," but filing text confirms "Access Pharmaceuticals, Inc.")
Reporting Period: Quarter and six months ended June 30, 2006.
Business Overview: An emerging pharmaceutical company focused on oncology and vitamin-targeted drug delivery technologies. The company sold its oral care and dermatology business unit to Uluru, Inc. in October 2005 to focus on core technologies. The company has been unprofitable since inception with an accumulated deficit of $74.4 million as of June 30, 2006.

Key Financial Metrics

Cash Flow: Net cash used in operating activities was $3.3 million for the six months ended June 30, 2006. Net cash provided by financing activities was $4.5 million, primarily from the issuance of secured convertible notes.

Material Changes vs. Prior Period

• Net Loss: For the six months ended June 30, 2006, the net loss increased by $1.96 million compared to the same period in 2005. This increase is largely attributed to a $2.24 million unrealized loss on the fair value of warrants and conversion features associated with new debt.
• Operating Expenses: General and administrative expenses decreased by $1.18 million for the six-month period compared to 2005, driven by the absence of former CEO separation costs ($839,000) and lower professional fees.
• Interest Expense: Interest and other expenses increased by $2.51 million year-over-year due to the addition of new secured convertible notes.
• Discontinued Operations: The 2005 period included a loss of $1.62 million from discontinued operations (oral/topical business), which was sold in October 2005. No discontinued operations were reported in 2006.

Guidance, Outlook, Risks, and Contingencies

Liquidity and Going Concern: Management states it does not have sufficient funds to repay convertible notes due in March and April 2007 or interest due in September 2006. The company expects existing resources (including receivables from Uluru, Inc.) to fund operations for approximately nine months, excluding debt obligations. Auditors have expressed significant doubt about the company's ability to continue as a going concern.

Financing Activities:

• SCO Capital Partners: Issued $5.0 million in 7.5% convertible notes due March 31, 2007, and warrants. Net proceeds were $4.5 million.
• SEDA: A Standby Equity Distribution Agreement with Cornell Capital Partners allows for up to $15 million in equity financing. However, the company cannot currently access this facility until a post-effective amendment to its registration statement is declared effective by the SEC.

Risks:

• Debt Default: Failure to restructure debt or raise capital could lead to default, foreclosure on assets, and bankruptcy.
• Internal Controls: The company reported two material weaknesses in internal controls (inadequate staffing and lack of segregation of duties) which management is addressing.
• Development Risk: No operating revenue is expected in the short term. Success depends on clinical trials for ProLindac(TM) and other candidates, which face regulatory and technical uncertainties.

Investor Verification Checklist

• Debt Maturity Dates: Verify the specific repayment terms and maturity dates for the $5.0 million SCO notes (March 2007) and the $4.0 million notes due April 2007.
• SEDA Status: Confirm the status of the post-effective amendment required to access the $15 million Standby Equity Distribution Agreement.
• Uluru Receivables: Monitor the collection of the remaining $3.7 million milestone payment due from Uluru, Inc., which is contingent on the absence of future liabilities.
• Cash Burn Rate: Validate the projected cash burn rate of approximately $625,000 per month against actual quarterly spending.
• Internal Controls Remediation: Review subsequent filings to confirm the hiring of staff and implementation of segregation of duties to address material weaknesses.